F Vincenti

Summary

Affiliation: University of California
Country: USA

Publications

  1. pmc Belatacept for prevention of acute rejection in adult patients who have had a kidney transplant: an update
    David Wojciechowski
    Kidney Transplant Service, University of California, San Francisco, CA, USA
    Biologics 6:385-93. 2012
  2. doi Are calcineurin inhibitors-free regimens ready for prime time?
    Flavio Vincenti
    University of California, San Francisco, Kidney Transplant Service, San Francisco, California 94143 0780, USA
    Kidney Int 82:1054-60. 2012
  3. doi Randomized phase 2b trial of tofacitinib (CP-690,550) in de novo kidney transplant patients: efficacy, renal function and safety at 1 year
    F Vincenti
    University of California, San Francisco, USA
    Am J Transplant 12:2446-56. 2012
  4. doi Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients
    F Vincenti
    University of California, San Francisco, Kidney Transplant Service, San Francisco, CA, USA
    Am J Transplant 12:210-7. 2012
  5. doi Novel B cell therapeutic targets in transplantation and immune-mediated glomerular diseases
    Flavio Vincenti
    University of California, San Francisco, Kidney Transplant Service, 505 Parnassus Avenue, M884, San Francisco, CA 94143 0780, USA
    Clin J Am Soc Nephrol 5:142-51. 2010
  6. doi A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study)
    F Vincenti
    Kidney Transplant Service, University of California San Francisco, San Francisco, CA, USA
    Am J Transplant 10:535-46. 2010
  7. pmc Five-year safety and efficacy of belatacept in renal transplantation
    Flavio Vincenti
    Division of Nephrology, University of California, San Francisco, 505 Parnassus Avenue, Moffitt 884, San Francisco, CA 94143 0780, USA
    J Am Soc Nephrol 21:1587-96. 2010
  8. doi Belatacept
    Flavio Vincenti
    University of California, San Francisco, 505 Parnassus Ave, Moffitt 884 San Francisco, California 94143 0780, USA
    Nat Rev Drug Discov 10:655-6. 2011
  9. doi What's next in the pipeline
    F Vincenti
    University of California, San Francisco, Kidney Transplant Service, San Francisco, CA, USA
    Am J Transplant 8:1972-81. 2008
  10. doi Calcineurin-inhibitor-free immunosuppression based on the JAK inhibitor CP-690,550: a pilot study in de novo kidney allograft recipients
    S Busque
    Stanford University School of Medicine, Stanford, CA, USA
    Am J Transplant 9:1936-45. 2009

Detail Information

Publications22

  1. pmc Belatacept for prevention of acute rejection in adult patients who have had a kidney transplant: an update
    David Wojciechowski
    Kidney Transplant Service, University of California, San Francisco, CA, USA
    Biologics 6:385-93. 2012
    ..Therefore, belatacept can be recommended for use in Epstein-Barr virus antibody-positive recipients...
  2. doi Are calcineurin inhibitors-free regimens ready for prime time?
    Flavio Vincenti
    University of California, San Francisco, Kidney Transplant Service, San Francisco, California 94143 0780, USA
    Kidney Int 82:1054-60. 2012
    ..Novel biologics such as ASKP1240 (a human anti-CD40 monoclonal antibody) and one small molecule, tofacitinib, may advance further the use of CNI-free regimens in organ transplantation...
  3. doi Randomized phase 2b trial of tofacitinib (CP-690,550) in de novo kidney transplant patients: efficacy, renal function and safety at 1 year
    F Vincenti
    University of California, San Francisco, USA
    Am J Transplant 12:2446-56. 2012
    ..Tofacitinib was equivalent to CsA in preventing acute rejection, was associated with improved renal function and less chronic allograft histological injury, but had side-effects at the doses evaluated...
  4. doi Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients
    F Vincenti
    University of California, San Francisco, Kidney Transplant Service, San Francisco, CA, USA
    Am J Transplant 12:210-7. 2012
    ..Belatacept-treated patients maintained a high rate of patient and graft survival that was comparable to cyclosporine-treated patients, despite an early increased occurrence of acute rejection and PTLD...
  5. doi Novel B cell therapeutic targets in transplantation and immune-mediated glomerular diseases
    Flavio Vincenti
    University of California, San Francisco, Kidney Transplant Service, 505 Parnassus Avenue, M884, San Francisco, CA 94143 0780, USA
    Clin J Am Soc Nephrol 5:142-51. 2010
    ..A new era of selective and more effective immunosuppression agents that target the humoral response is finally emerging in transplantation and renal diseases...
  6. doi A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study)
    F Vincenti
    Kidney Transplant Service, University of California San Francisco, San Francisco, CA, USA
    Am J Transplant 10:535-46. 2010
    ..Belatacept was associated with superior renal function and similar patient/graft survival versus cyclosporine at 1 year posttransplant, despite a higher rate of early acute rejection...
  7. pmc Five-year safety and efficacy of belatacept in renal transplantation
    Flavio Vincenti
    Division of Nephrology, University of California, San Francisco, 505 Parnassus Avenue, Moffitt 884, San Francisco, CA 94143 0780, USA
    J Am Soc Nephrol 21:1587-96. 2010
    ..In conclusion, this study demonstrated high patient persistence with intravenous belatacept, stable renal function, predictable pharmacokinetics, and good safety with belatacept over 5 years...
  8. doi Belatacept
    Flavio Vincenti
    University of California, San Francisco, 505 Parnassus Ave, Moffitt 884 San Francisco, California 94143 0780, USA
    Nat Rev Drug Discov 10:655-6. 2011
    ....
  9. doi What's next in the pipeline
    F Vincenti
    University of California, San Francisco, Kidney Transplant Service, San Francisco, CA, USA
    Am J Transplant 8:1972-81. 2008
    ..The preclinical pipeline is not only full but promises to address previously neglected targets and fulfill unmet medical needs in transplant therapeutics...
  10. doi Calcineurin-inhibitor-free immunosuppression based on the JAK inhibitor CP-690,550: a pilot study in de novo kidney allograft recipients
    S Busque
    Stanford University School of Medicine, Stanford, CA, USA
    Am J Transplant 9:1936-45. 2009
    ..At 15 mg BID, the efficacy/safety profile was comparable to the tacrolimus control group, excepting a higher rate of viral infection. Further dose-ranging evaluation of CP-690,550 is warranted...
  11. ncbi Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus
    F Vincenti
    University of California San Francisco Kidney Transplant Service, San Francisco, CA, USA
    Am J Transplant 7:1506-14. 2007
    ..The incidence of NODAT or IFG at 6 months post-transplant is significantly lower with CsA-ME than with tacrolimus without a significant difference in short-term outcome...
  12. ncbi Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation
    F Vincenti
    University of California, San Francisco, USA
    Transplantation 71:1282-7. 2001
    ....
  13. doi A randomized, multicenter study of steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney transplant recipients
    F Vincenti
    University of California San Francisco, San Francisco, CA, USA
    Am J Transplant 8:307-16. 2008
    ....
  14. pmc The effect of costimulatory and interleukin 2 receptor blockade on regulatory T cells in renal transplantation
    J A Bluestone
    Diabetes Center, Department of Medicine, University of California San Francisco, CA, USA
    Am J Transplant 8:2086-96. 2008
    ....
  15. ncbi Living donor kidney transplant recipients and clinical trials: participation profiles and impact on post-transplant care
    T V Brennan
    Department of Surgery, Division of Transplantation, University of California San Francisco, San Francisco, California, USA
    Am J Transplant 6:2429-35. 2006
    ..Overall graft and patient survival were comparable. We conclude that clinical trial participants were disproportionately male, had increased intensity of post-transplant care but comparable outcomes to nonparticipants...
  16. ncbi A phase I/II randomized open-label multicenter trial of efalizumab, a humanized anti-CD11a, anti-LFA-1 in renal transplantation
    F Vincenti
    Transplant Service, University of California, San Francisco, CA, USA
    Am J Transplant 7:1770-7. 2007
    ..The two doses of efalizumab resulted in comparable saturation and modulation of CD11a. This phase II trial suggests that efalizumab may warrant further investigation in transplantation...
  17. ncbi De novo use of sirolimus in immunosuppression regimens in kidney and kidney-pancreas transplantation at the University of California, San Francisco
    F Vincenti
    University of California, San Francisco, Kidney Transplant Service, San Francisco, California, USA
    Transplant Proc 35:183S-186S. 2003
    ..This steroid-free maintenance regimen has been used in the last 30 enteric-drained, simultaneous pancreas-kidney transplants. Using this immunosuppressive approach, rejection rates are less than 10% for either the kidney or the pancreas...
  18. ncbi Rituximab failed to improve nephrotic syndrome in renal transplant patients with recurrent focal segmental glomerulosclerosis
    J M Yabu
    Department of Medicine, University of California, San Francisco, CA, USA
    Am J Transplant 8:222-7. 2008
    ..None of the patients treated with rituximab achieved remission in proteinuria, and one patient experienced early graft loss. In these four adult renal transplant patients with recurrent FSGS, rituximab failed to diminish proteinuria...
  19. ncbi Optimizing the use of cyclosporine (Neoral) for recipients of living donor kidneys
    F Vincenti
    Kidney Transplant Service, University of California San Francisco, San Francisco, CA 94143 0780, USA
    Transplant Proc 36:50S-53S. 2004
  20. ncbi Prospective, multicenter, randomized trial to compare incidence of new-onset diabetes mellitus and glucose metabolism in patients receiving cyclosporine microemulsion versus tacrolimus after de novo kidney transplantation
    F Vincenti
    Kidney Transplant Service, UCSF, San Francisco, California 94143, USA
    Transplant Proc 37:1001-4. 2005
    ..At 3 months, median GFR (Nankivell) was 63.7 mL/min; median serum creatinine was 137 micromol/L. Full complete results are expected in December 2005...
  21. ncbi New monoclonal antibodies in renal transplantation
    F Vincenti
    Kidney Transplant Service, University of California, San Francisco, CA 94143 0780, USA
    Minerva Urol Nefrol 55:57-66. 2003
    ....
  22. doi Immunosuppression with belatacept-based, corticosteroid-avoiding regimens in de novo kidney transplant recipients
    R Ferguson
    Ohio State University College of Medicine, Columbus, OH, USA
    Am J Transplant 11:66-76. 2011
    ....